Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK
Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.
Eur Respir Rev. 2020 Nov 5;29(158). doi: 10.1183/16000617.0199-2020. Print 2020 Dec 31.
The 2019 coronavirus disease (COVID-19) pandemic is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Clinical outcomes, including mortality, are worse in males, older individuals and patients with comorbidities. COPD patients are included in shielding strategies due to their susceptibility to virus-induced exacerbations, compromised pulmonary function and high prevalence of associated comorbidities. Using evidence from basic science and cohort studies, this review addresses key questions concerning COVID-19 and COPD. First, are there mechanisms by which COPD patients are more susceptible to SARS-CoV-2 infection? Secondly, do inhaled corticosteroids offer protection against COVID-19? And, thirdly, what is the evidence regarding clinical outcomes from COVID-19 in COPD patients? This up-to-date review tackles some of the key issues which have significant impact on the long-term outlook for COPD patients in the context of COVID-19.
2019 冠状病毒病（COVID-19）大流行是由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的。临床结局，包括死亡率，在男性、老年人和合并症患者中更差。由于 COPD 患者易发生病毒诱发的加重、肺功能受损和相关合并症的高患病率，因此他们被纳入了防护策略。本综述利用基础科学和队列研究的证据，解决了有关 COVID-19 和 COPD 的关键问题。首先，是否存在 COPD 患者更容易感染 SARS-CoV-2 的机制？其次，吸入皮质类固醇是否能预防 COVID-19？第三，关于 COVID-19 对 COPD 患者的临床结局有哪些证据？本最新综述针对一些关键问题进行了探讨，这些问题对 COVID-19 大流行背景下 COPD 患者的长期预后有重大影响。
